Carney Colleen E, Edinger Jack D, Kuchibhatla Maragatha, Lachowski Angela M, Bogouslavsky Olya, Krystal Andrew D, Shapiro Colin M
Ryerson University.
National Jewish Health.
Sleep. 2017 Apr 1;40(4). doi: 10.1093/sleep/zsx019.
To compare cognitive behavioral therapy for insomnia (CBT-I) + antidepressant medication (AD) against treatments that target solely depression or solely insomnia.
A blinded, randomized split-plot experimental study.
Two urban academic clinical centers.
107 participants (68% female, mean age 42 ± 11) with major depressive disorder and insomnia.
Randomization was to one of three groups: antidepressant (AD; escitalopram) + CBT-I (4 sessions), CBT-I + placebo pill, or AD + 4-session sleep hygiene control (SH).
Subjective sleep was assessed via 2 weeks of daily sleep diaries (use of medication was covaried in all analyses); although there were no statistically significant group differences detected, all groups improved from baseline to posttreatment on subjective sleep efficiency (SE) and total wake time (TWT) and the effect sizes were large. Objective sleep was assessed via overnight polysomnographic monitoring at baseline and posttreatment; analyses revealed both CBT groups improved on TWT (p = .03), but the AD + SH group worsened. There was no statistically significant effect for PSG SE (p = .07). There was a between groups medium effect observed for the AD + SH and CBT + placebo group differences on diary TWT and both PSG variables. All groups improved significantly from baseline to posttreatment on the Hamilton Rating Scale for Depression (HAMD-17); the groups did not differ.
Although all groups self-reported sleeping better after treatment, only the CBT-I groups improved on objective sleep, and AD + SH's sleep worsened. This suggests that we should be treating sleep in those with depression with an effective insomnia treatment and relying on self-report obscures sleep worsening effects. All groups improved on depression, even a group with absolutely no depression-focused treatment component (CBT-I + placebo). The depression effect in CBT-I only group has been reported in other studies, suggesting that we should further investigate the antidepressant properties of CBT-I.
比较失眠认知行为疗法(CBT-I)+抗抑郁药物(AD)与仅针对抑郁或仅针对失眠的治疗方法。
一项双盲、随机裂区实验研究。
两个城市学术临床中心。
107名患有重度抑郁症和失眠的参与者(68%为女性,平均年龄42±11岁)。
随机分为三组之一:抗抑郁药(AD;艾司西酞普兰)+CBT-I(4次治疗)、CBT-I+安慰剂丸或AD+4次睡眠卫生控制(SH)。
通过2周的每日睡眠日记评估主观睡眠(在所有分析中对药物使用情况进行协变量分析);尽管未检测到统计学上的显著组间差异,但所有组在主观睡眠效率(SE)和总觉醒时间(TWT)方面从基线到治疗后均有所改善,且效应量较大。通过基线和治疗后的夜间多导睡眠图监测评估客观睡眠;分析显示两个CBT组在TWT方面有所改善(p = 0.03),但AD + SH组恶化。对于多导睡眠图SE没有统计学上的显著影响(p = 0.07)。在日记TWT以及两个多导睡眠图变量方面,观察到AD + SH组和CBT + 安慰剂组之间存在中等效应。所有组在汉密尔顿抑郁评定量表(HAMD-17)上从基线到治疗后均有显著改善;各组之间无差异。
尽管所有组在治疗后自我报告睡眠有所改善,但只有CBT-I组在客观睡眠方面有所改善,而AD + SH组的睡眠恶化。这表明我们应该用有效的失眠治疗方法来治疗抑郁症患者的睡眠问题,而仅依靠自我报告掩盖了睡眠恶化的影响。所有组在抑郁方面均有改善,甚至是一个完全没有针对抑郁治疗成分的组(CBT-I + 安慰剂)。CBT-I仅治疗组的抑郁效应在其他研究中也有报道,这表明我们应该进一步研究CBT-I的抗抑郁特性。